Analysts Viewpoint
Crinetics Pharmaceuticals Inc (CRNX) receives a Buy rating from Citigroup
In a filing, Crinetics Pharmaceuticals Inc revealed its Chief Med and Dev Officer Pizzuti Dana unloaded Company’s shares for reported
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.